Cardiorenal

Do Beta-Blockers Help in Heart Failure with Preserved Ejection Fraction?

Quick answer

Beta-blockers have not improved outcomes in HFpEF-dedicated trials (SENIORS HFpEF subgroup, observational meta-analyses). Continue only for another indication — rate control in AFib, prior MI, or refractory hypertension. Deprescribe when chronotropic incompetence limits exercise capacity, particularly in HFpEF with baseline resting HR <70.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

SENIORS HFpEF subgroup (2009)

PMID 20609652

643 with LVEF >35% within 2,128 total (nebivolol)

No significant reduction in all-cause mortality or CV hospitalization (HR 0.81, 95% CI 0.63–1.04). Benefit confined to reduced-EF subgroup.

Cleland et al. meta-analysis (2018)

PMID 29040525

18,637 patients from 11 trials, LVEF ≥40% subgroup

Beta-blockers did not reduce mortality in HFpEF (HR 1.00, 95% CI 0.81–1.23) in patients in sinus rhythm.

Practical decision algorithm

IfThen
HFpEF + AFib with rapid ventricular rateContinue beta-blocker for rate control — target 80–110 bpm.
HFpEF + prior MI or significant CADContinue for secondary prevention (class 1 indication in CAD).
HFpEF + uncontrolled HTNBeta-blocker reasonable but MRA, ARNI, or chlorthalidone often more effective.
HFpEF in sinus rhythm, no MI history, resting HR <70, exertional fatigueConsider tapering beta-blocker over 2–4 weeks while monitoring BP and symptoms.
HFpEF + atrial tachyarrhythmia with chronotropic incompetenceTry dose reduction or switch to calcium channel blocker (diltiazem) for rate control.

Guideline position

2022 AHA/ACC/HFSA HF guideline: no class indication for beta-blocker in HFpEF. ESC 2021 HF guideline: beta-blockers not recommended for HFpEF unless indication for another condition. 2023 ACC consensus on HFpEF: individualized deprescribing reasonable when chronotropic incompetence limits quality of life.

Contraindications and cautions

  • Severe bradycardia (<50 bpm) without pacing
  • High-grade AV block without pacing
  • Severe reactive airway disease (cardioselective preferred if needed)
  • Decompensated HF with hypotension
  • Cocaine-induced chest pain (acute)

Frequently asked questions

Does beta-blocker withdrawal cause rebound events?
Taper over 2–4 weeks to avoid sympathetic rebound. Rebound ischemia is primarily a concern in CAD; monitor BP and symptoms during taper.
Is nebivolol different because of nitric oxide effects?
Theoretically yes — vasodilatory properties could help HFpEF. SENIORS HFpEF subgroup did not confirm benefit. Insufficient evidence to recommend over other beta-blockers.
What about chronotropic incompetence — how do I diagnose?
Failure to reach 80% of age-predicted max HR on exercise testing, or rise <0.8 × (220 − age − resting HR). In HFpEF, it is common and contributes to exercise intolerance.
Should I add SGLT2 inhibitor before or after deprescribing?
Add SGLT2 inhibitor first. It is guideline-directed therapy in HFpEF (EMPEROR-Preserved, DELIVER) and provides mortality/hospitalization reduction regardless of beta-blocker status.
Is the picture different in HFmrEF (EF 41–49)?
Some benefit appears in the EF 41–49 range — the meta-analysis showed mortality reduction in sinus rhythm. Reasonable to continue beta-blocker in HFmrEF if tolerated.

Further reading

Evidence-Based Medicine

SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points

Clinical Reasoning

Chronic Heart Failure Monitoring: NT-proBNP Guided Therapy

Evidence-Based Medicine

Atrial Fibrillation: Rate vs Rhythm Control in 2026 — EAST-AFNET 4 and Beyond

Back to all decision points